Use of palivizumab in infants and young children with severe respiratory disease: A delphi study

Pediatric Pulmonology

Volumn 49, Issue 5, 2014, Pages 490-502

  Gaboli, Mirella ^a   De La Cruz, Òscar Asensio ^b   De Agüero, María Isabel Barrio Gõmez ^c   Moreno Galdõ, Antonio ^d   Pérez, Guadalupe Pérez ^e   De Querol, Manuel Sánchez Solís ^f  

^a HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^d HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^e HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

^f HOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA   (Spain)

Author keywords

infant; prophylaxis; respiratory syncytial virus infection; young children

Indexed keywords

OXYGEN; PALIVIZUMAB; ANTIVIRUS AGENT; MONOCLONAL ANTIBODY;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; ASTHMA; CHILDHOOD DISEASE; CONGENITAL LUNG DISEASE; CONSENSUS DEVELOPMENT; CYSTIC FIBROSIS; DELPHI STUDY; DIAPHRAGM HERNIA; ESOPHAGUS ATRESIA; FEEDBACK SYSTEM; GRAFT RECIPIENT; HUMAN; INFANT DISEASE; INFECTION PREVENTION; LUNG MALFORMATION; NEUROMUSCULAR DISEASE; OFF LABEL DRUG USE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; PULMONOLOGIST; QUESTIONNAIRE; RESPIRATORY SYNCYTIAL VIRUS INFECTION; RESPIRATORY TRACT DISEASE; STORAGE DISEASE; TRACHEOESOPHAGEAL FISTULA; TRACHEOMALACIA; TREATMENT RESPONSE; WHEEZING; CHRONIC DISEASE; COMPLICATION; INFANT; LUNG DISEASE; PEDIATRICS; PRESCHOOL CHILD; PROCEDURES; PULMONOLOGY; RESPIRATORY FAILURE; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; SEVERITY OF ILLNESS INDEX;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIVIRAL AGENTS; CHILD, PRESCHOOL; CHRONIC DISEASE; DELPHI TECHNIQUE; HUMANS; INFANT; LUNG DISEASES; OFF-LABEL USE; PEDIATRICS; PULMONARY MEDICINE; RESPIRATORY INSUFFICIENCY; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; SEVERITY OF ILLNESS INDEX;

EID: 84898600212     PISSN: 87556863     EISSN: 10990496     Source Type: Journal    
DOI: 10.1002/ppul.22826     Document Type: Article

References (59)

1. Wright M, Piedimonte G,. Respiratory syncytial virus prevention and therapy: past, present, and future. Pediatr Pulmonol 2011; 46: 324-347.
2. Mazoni P, Paes B, Resch B, Mejias A, Ramilo O, Carbonell-Estrany X, Bont L,. High risk for RSV bronchiolitis in late preterms and selected infants affected by rare disorders: a dilemma of specific prevention. Early Hum Dev 2012; 88 (Suppl 2): S34-S41.
3. Simon A, Prusseit J, Müller A,. Respiratory syncytial virus infection in children with neuromuscular impairment. Open Microbiol J 2011; 5: 155-158.
4. Kristensen K, Hjuler T, Ravn H, Simões EA, Stensballe LG,. Chronic diseases, chromosomal abnormalities, and congenital malformations as risk factors for respiratory syncytial virus hospitalization: a population-based cohort study. Clin Infect Dis 2012; 54: 810-817.
5. Sommer C, Resch B, Simões EA,. Risk factors for severe respiratory Syncytial Virus lower respiratory tract infection. Open Microbiol J 2011; 5: 144-154.
6. Thorburn K,. Pre-existing disease is associated with a significantly higher risk of death in severe respiratory syncytial virus (RSV) infection. Arch Dis Child 2009; 94: 99-103.
7. Resch B, Sommer C, Nuijten MJ, Seidinger S, Walter E, Schoellbauer V, Mueller WD,. Cost-effectiveness of palivizumab for respiratory syncytial virus infection in high-risk children, based on long-term epidemiologic data from Austria. Pediatr Infect Dis J 2012; 31: e1-e8.
8. The IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high risk infants. Pediatrics 1998; 102: 531-537.
9. Feltes TF, Cabalka AK, Meissner HC, Piazza FM, Carlin DA, Top FH Jr, Connor EM, Sondheimer HM,. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr 2003; 143: 532-540.
10. Figueras Aloy J, Lõpez Sastre J, Medrano Lõpez C, Bermúdez-Cañete Fernández R, Fernández Pinedab L, Bonillo Peralesc A, Pérez-Yarza EG, Díaz de Heredia C, Sánchez de Toledo J,. Spanish multidisciplinary consensus on the prevention of respiratory syncytial virus infection in children. An Pediatr (Barc) 2008; 69: 63-71.
11. Medrano Lõpez C, García-Guereta L, Fernández Pineda L, Malo Concepciõn P, Maroto Álvaro E, Santos de Soto J, Lirio Casero J, Suárez Cabrera P, Caballero Martínez J,. Clinical consensus on respiratory syncytial virus (RSV) infection prophylaxis and the use of palivizumab in paediatric cardiology. An Pediatr (Barc) 2010; 7: 432.e1-432.e13.
12. Mitha A, Boulyana M, Hue V, Pruvost I,., Martinot A, the European French-speaking expert group, Dubos F,. Consensus in diagnostic definitions for bone or joint infections in children by a Delphi method with European French-speaking experts. Acta Paediatr 2012; 101: e350-e356.
13. Stinson JN, Connelly M, Jibb LA, Schanberg LE, Walco G, Spiegel LR, Tse SM, Chalom EC, Chira P, Rapoff M,. Developing a standardized approach to the assessment of pain in children and youth presenting to pediatric rheumatology providers: a Delphi survey and consensus conference process followed by feasibility testing. Pediatr Rheumatol Online J 2012; 10: 7. doi: 10.1186/1546-0096-10-7
14. Neubert A, Wong IC, Bonifazi A, Catapano M, Felisi M, Baiardi P, Giaquinto C, Knibbe CA, Sturkenboom MC, Ghaleb MA, Ceci A,. Defining off-label and unlicensed use of medicines for children: results of a Delphi survey. Pharmacol Res 2008; 58: 316-322.
15. Wilson S, Ramelet AS, Zuiderduyn S,. Research priorities for nursing care of infants, children and adolescents: a West Australian Delphi study. J Clin Nurs 2010; 19: 1919-1928. doi: 10.1111/j.1365-2702.2009.03025.x
16. Verschuren O, Ketelaar M, Keefer D, Wright V, Butler J, Ada L, Maher C, Reid S, Wright M, Dalziel B, Wiart L, Fowler E, Unnithan V, Maltais DB, van den Berg-Emons R, Takken T,. Identification of a core set of exercise tests for children and adolescents with cerebral palsy: a Delphi survey of researchers and clinicians. Dev Med Child Neurol 2011; 53: 449-456. doi: 10.1111/j.1469-8749. 2010.03899.x
17. Dalkey N, Brown B, Cochran S,. The Delphi method, III: use of self ratings to improve group estimates. Santa Monica, CA: Rand Corp.; 1969. Publication RM-6115-PR.
18. Holey EA, Feeley JL, Dixon J, Whittaker VJ,. An exploration of the use of simple statistics to measure consensus and stability in Delphi studies. BMC Med Res Methodol 2007; 7: 52. doi 10.1186/1471-2288-7-52
19. Fick DM, Cooper JW, Wade WE, Waller JL, Maclean JR, Beers MH,. Updating the Beers criteria for potentially inappropriate medication use in older adults: results of a US consensus panel of experts. Arch Intern Med 2003; 263: 2716-2724.
20. Royle P, Waugh N,. Literature searching for clinical and cost-effectiveness studies used in health technology assessment reports carried out for the National Institute for Clinical Excellence appraisal system. Health Technol Assess 2003; 7: 1-51.
21. Castro-Rodriguez JA,. The Asthma Predictive Index: a very useful tool for predicting asthma in young children. J Allergy Clin Immunol 2010; 126: 212-216.
22. Prasad SA, Main E, Dodd ME,. Finding consensus on the physiotherapy management of asymptomatic infants with cystic fibrosis. Pediatr Pulmonol 2008; 43: 236-244.
23. Fitzgerald DA,. Preventing RSV bronchiolitis in vulnerable infants: the role of palivizumab. Paediatr Respir Rev 2009; 10: 143-147.
24. Committee on Infectious Diseases. From the American Academy of Pediatrics: Policy statements-modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infections. Pediatrics 2009; 124: 1694-1701.
25. Wilkesmann A, Ammann RA, Schildgen O, Eis-Hübinger AM, Müller A, Seidenberg J, Stephan V, Rieger C, Herting E, Wygold T, Hornschuh F, Groothuis JR, Simon A,. Hospitalized children with respiratory syncytial virus infection and neuromuscular impairment face an increased risk of a complicated course. Pediatr Infect Dis J 2007; 26: 485-491.
26. Resch B, Manzoni P, Lanari M,. Severe respiratory syncytial virus (RSV) infection in infants with neuromuscular diseases and immune deficiency syndromes. Paediatr Respir Rev 2009; 10: 148-153.
27. Paes B, Mitchell I, Li A, Lanctôt KL,. Respiratory hospitalizations and respiratory syncytial virus prophylaxis in special populations. Eur J Paediatr 2012; 171: 833-841.
28. Megged O, Schlesinger Y,. Down syndrome and respiratory syncytial virus infection. Pediatr Infect Dis J 2010; 29: 672-673.
29. Zachariah P, Ruttenber M, Simões EA,. Hospitalizations due to respiratory syncytial virus in children with congenital malformations. Pediatr Infect Dis 2011; 30: 442-445.
30. Mori M, Kawashima H, Nakamura H, Nakagawa M, Kusuda S, Saji T, Tsutsumi H, Yokota S, Itoh S,. Nationwide survey of severe respiratory syncytial virus infection in children who do not meet indications for palivizumab in Japan. J Infect Chemother 2011; 17: 254-263.
31. Bloemers BL, van Furth AM, Weijerman ME, Gemke RJ, Broers CJ, van den Ende K, Kimpen JL, Strengers JL, Bont LJ,. Down syndrome: a novel risk factor for respiratory syncytial virus bronchiolitis-a prospective birth-cohort study. Pediatrics 2007; 120: e1076-e1081.
32. Zachariah P, Ruttenber M, Simões EA,. Down syndrome and hospitalizations due to respiratory syncytial virus: a population-based study. J Pediatr 2012; 160: 827-831.e1. Epub December 16, 2011.
33. Smyth AR, Smyth RL, Tong CY, Hart CA, Heaf DP,. Effect of respiratory virus infections including rhinovirus on clinical status in cystic fibrosis. Arch Dis Child 1995; 73: 117-120.
34. Armstrong DS, Grimwood K, Carlin JB, Carzino R, Gutièrrez JP, Hull J, Olinsky A, Phelan EM, Robertson CF, Phelan PD,. Lower airway inflammation in infants and young children with cystic fibrosis. Am J Respir Crit Care Med 1997; 156: 1197-1204.
35. Van Ewijk BE, Wolfs TF, Aerts PC, Van Kessel KP, Fleer A, Kimpen JL, Van der Ent CK,. RSV mediates Pseudomonas aeruginosa binding to cystic fibrosis and normal epithelial cells. Pediatr Res 2007; 61: 398-403.
36. Winterstein AG, Eworuke E, Xu D, Schuler P,. Palivizumab immunoprophylaxis effectiveness in children with cystic fibrosis. Pediatr Pulmonol 2012; doi: 10.1002/ppul.22711 [Epub ahead of print].
37. Robinson KA, Odelola OA, Saldanha IJ, Mckoy NA,. Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis (review). Cochrane Database Syst Rev 2012; CD007743. doi: 10.1002/14651858.CD007743.pub3
38. Dharmaraj P, Smyth RL,. Vaccines for preventing influenza in people with cystic fibrosis. Cochrane Database Syst Rev 2009; CD001753. doi: 10.1002/14651858.CD001753.pub2
39. American Academy of Pediatrics, Committee on Infectious Diseases. Prevention of influenza: recommendations for influenza immunization of children, 2007-2008. Pediatrics 2008; 121: e1016. doi: 10.1542/peds.2008-0160
40. Malfroot A, Adam G, Ciofu O, Döring G, Knoop C, Lang AB, Van Damme P, Dab I, Bush A,. Immunisation in the current management of cystic fibrosis patients. J Cyst Fibros 2005; 4: 77-87.
41. Giebels K, Marcotte JE, Podoba J, Rousseau C, Denis MH, Fauvel V, Laberge S,. Prophylaxis against respiratory syncytial virus in young children with cystic fibrosis. Pediatr Pulmonol 2008; 43: 169-174.
42. Masumoto K, Nagata K, Uesugi T, Yamada T, Kinjo T, Hikino S, Hara T, Taguchi T,. Risk of respiratory syncytial virus in survivors with severe congenital diaphragmatic hernia. Pediatr Int 2008; 50: 459-463.
43. Mitchell I, Paes BA, Li A, Lanctôt KL,. CARESS: the Canadian registry of palivizumab. Pediatr Infect Dis J 2011; 30: 651-655.
44. Vu DL, Bridevaux PO, Aubert JD, Soccal PM, Kaiser L,. Respiratory viruses in lung transplant recipients: a critical review and pooled analysis of clinical studies. Am J Transplant 2011; 11: 1071-1078.
45. Soccal PM, Aubert JD, Bridevaux PO, Garbino J, Thomas Y, Rochat T, Rochat TS, Meylan P, Tapparel C, Kaiser L,. Upper and lower respiratory tract viral infections and acute graft rejection in lung transplant recipients. Clin Infect Dis 2010; 51: 163-170.
46. Kumar D, Erdman D, Keshavjee S, Peret T, Tellier R, Hadjiliadis D, Johnson G, Ayers M, Siegal D, Humar A,. Clinical impact of community-acquired respiratory viruses on bronchiolitis obliterans after lung transplant. Am J Transplant 2005; 5: 2031-2036.
47. Michaels MG, Fonseca-Aten M, Green M, Charsha-May D, Friedman B, Seikaly M, Sánchez PJ,. Respiratory syncytial virus prophylaxis: a survey of pediatric solid organ transplant centers. Pediatr Transplant 2009; 13: 451-456.
48. Danziger-Isakov LA, Arslan D, Sweet S, Benden C, Goldfarb S, Wong J,. RSV prevention and treatment in pediatric lung transplant patients: a survey of current practices among the International Pediatric Lung Transplant Collaborative. Pediatr Transplant 2012; 16: 638-644.
49. Cabalka AK,. Physiologic risk factors for respiratory viral infections and immunoprophylaxis for respiratory syncytial virus in young children with congenital heart disease. Pediatr Infect Dis J 2004; 23 (Suppl): S41-S45.
50. Chantepie A,. Use of palivizumab for the prevention of respiratory syncytial virus infections in children with congenital heart disease. Recommendations from the French Paediatric Cardiac Society [Article in French]. Arch Pediatr 2004; 11: 1402-1405.
51. Simoes EA, Groothuis JR, Carbonell-Estrany X, Rieger CH, Mitchell I, Fredrick LM, Kimpen JL,. Palivizumab prophylaxis, respiratory syncytial virus, and subsequent recurrent wheezing. J Pediatr 2007; 151: 34-42.
52. Simões EA, Carbonell-Estrany X, Rieger CH, Mitchell I, Fredrick L, Groothuis JR,. The effect of respiratory syncytial virus on subsequent recurrent wheezing in atopic and nonatopic children. J Allergy Clin Immunol 2010; 126: 256-262.
53. Malley R, DeVincenzo J, Ramilo O, Dennehy PH, Meissner HC, Gruber WC, Sanchez PJ, Jafri H, Balsley J, Carlin D, Buckingham S, Vernacchio L, Ambrosino DM,. Reduction of respiratory syncytial virus (RSV) in tracheal aspirates in intubated infants by use of humanized monoclonal antibody to RSV F protein. J Infect Dis 1998; 178: 1555-1561.
54. Boeckh M, Berrey MM, Bowden RA, Crawford SW, Balsley J, Corey L,. Phase 1 evaluation of the respiratory syncytial virus-specific monoclonal antibody palivizumab in recipients of hematopoietic stem cell transplants. J Infect Dis 2001; 184: 350-354.
55. Subramanian KN, Weisman LE, Rhodes T, Ariagno R, Sánchez PJ, Steichen J, Givner LB, Jennings TL, Top FH Jr, Carlin D, Connor E, MEDI-493 Study Group. Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. Pediatr Infect Dis J 1998; 17: 110-115.
56. Faber TE, Kimpen JL, Bont LJ,. Respiratory syncytial virus bronchiolitis: prevention and treatment. Expert Opin Pharmacother 2008; 9: 2451-2458.
57. Sáez-Llorens X, Moreno MT, Ramilo O, Sánchez PJ, Top FH Jr, Connor EM, MEDI-493 Study Group. Safety and pharmacokinetics of palivizumab therapy in children hospitalized with respiratory syncytial virus infection. Pediatr Infect Dis J 2004; 23: 707-712.
58. Chávez-Bueno S, Mejías A, Merryman RA, Ahmad N, Jafri HS, Ramilo O,. Intravenous palivizumab and ribavirin combination for respiratory syncytial virus disease in high-risk pediatric patients. Pediatr Infect Dis J 2007; 26: 1089-1093.
59. Tsitsikas DA, Oakervee H, Cavenagh JD, Gribben J, Agrawal SG, Mattes FM,. Treatment of respiratory syncytial virus infection in haemopoietic stem cell transplant recipients with aerosolized ribavirin and the humanized monoclonal antibody palivizumab: a single centre experience. Br J Haematol 2009; 146: 574-576.